NCT00146757View on ClinicalTrials.gov

A Study Evaluating the Safety and Pharmacokinetics of Aldurazyme® (Laronidase) in MPS I Patients Less Than 5 Years Old

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2002

Primary Completion Date

May 31, 2005

Study Completion Date

May 31, 2005

Conditions

Mucopolysaccharidosis IHurler SyndromeHurler-Scheie SyndromeScheie Syndrome

Interventions

BIOLOGICAL

Aldurazyme (Recombinant Human Alpha-L-Iduronidase)

100 U/kg every week

BIOLOGICAL

Aldurazyme (Recombinant Human Alpha-L-Iduronidase)

200 U/kg every week (Week 26 onwards)

Trial Locations (4)

Unknown

Hôpital E. Herriot, Lyon

Johannes Gutenberg Universität, Kinderklinik

Sophia Children's Hospital, Rotterdam

Willink Biochemical Genetics Unit Royal Hospital for Children, Manchester

All Listed Sponsors

collaborator

BioMarin/Genzyme LLC

INDUSTRY

lead

Genzyme, a Sanofi Company

INDUSTRY

NCT00146757 - A Study Evaluating the Safety and Pharmacokinetics of Aldurazyme® (Laronidase) in MPS I Patients Less Than 5 Years Old | Biotech Hunter | Biotech Hunter